Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment

Raymond Niaura*, Bonnie Spring, Belinda Borrelli, Donald Hedeker, Michael G. Goldstein, Nancy Keuthen, Judy Depue, Jean Kristeller, Judy Ockene, Allan Prochazka, John A. Chiles, David B. Abrams

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

77 Scopus citations

Abstract

The authors evaluated the efficacy of fluoxetine hydrochloride (Prozac; Eli Lilly and Company, Indianapolis, IN) as an adjunct to behavioral treatment for smoking cessation. Sixteen sites randomized 989 smokers to 3 dose conditions: 10 weeks of placebo, 30 mg, or 60 mg fluoxetine per day. Smokers received 9 sessions of individualized cognitive-behavioral therapy, and biologically verified 7-day self-reported abstinence follow-ups were conducted at 1, 3, and 6 months posttreatment. Analyses assuming missing data counted as smoking observed no treatment difference in outcomes. Pattern-mixture analysis that estimates treatment effects in the presence of missing data observed enhanced quit rates associated with both the 60-mg and 30-mg doses. Results support a modest, short-term effect of fluoxetine on smoking cessation and consideration of alternative models for handling missing data.

Original languageEnglish (US)
Pages (from-to)887-896
Number of pages10
JournalJournal of Consulting and Clinical Psychology
Volume70
Issue number4
DOIs
StatePublished - 2002

ASJC Scopus subject areas

  • Clinical Psychology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment'. Together they form a unique fingerprint.

Cite this